

Biological Reference Interval Units

PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251WJ001886 PATIENT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045 ABHA NO :	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04

Results

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP A	BOVE 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : CYANIDE FREE DETERMINATION	13.4	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : ELECTRICAL IMPEDANCE	4.74	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : ELECTRICAL IMPEDANCE	6.30	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : ELECTRONIC IMPEDANCE	220	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	41.2	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED PARAMETER	87.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	28.3	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	32.5	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : CALCULATED PARAMETER	13.9	11.6 - 14.0	%
MENTZER INDEX	18.4		
MEAN PLATELET VOLUME (MPV) METHOD : CALCULATED PARAMETER	7.3	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	56	40 - 80	%
LYMPHOCYTES METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	31	20 - 40	%
MONOCYTES	06	2 - 10	%

Test Report Status

<u>Final</u>

Dr. Akansha Jain **Consultant Pathologist**









PATIENT NAME : SUDHIR KASLIWAL	REF.	DOCTOR : SELF
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251WJ0 PATIENT ID : SUDHM211 CLIENT PATIENT ID: 01231021 ABHA NO :	L066251 DRAWN :21/10/2023 12:57:00
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units

07 High	1 - 6	%
00	0 - 2	%
3.53	2.0 - 7.0	thou/µL
1.95	1.0 - 3.0	thou/µL
0.38	0.2 - 1.0	thou/µL
0.44	0.02 - 0.50	thou/µL
0 Low	0.02 - 0.10	thou/µL
1.8		
	00 3.53 1.95 0.38 0.44 0 Low	00 0 - 2 3.53 2.0 - 7.0 1.95 1.0 - 3.0 0.38 0.2 - 1.0 0.44 0.02 - 0.50 0 Low 0.02 - 0.10

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) ì06504

This ratio element is a calculated parameter and out of NABL scope.



Dr. Akansha Jain **Consultant Pathologist**



Πü

Page 2 Of 17

View Report

View Details



с¢



PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR : S	SELF
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG IAIPUR 302017	PATIENT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04

Test Report	Status	<u>Final</u>
-------------	--------	--------------

Results

Biological Reference Interval Units

HAEMATOLOGY					
MEDI WHEEL FULL BODY HEALTH CHECK UP ABO	OVE 40 MALE				
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA W BLOOD	HOLE				
HBA1C	7.0 High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%		
METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) ESTIMATED AVERAGE GLUCOSE(EAG)	154.2 High	< 116.0	mg/dL		

METHOD : CALCULATED PARAMETER

Dr. Akansha Jain Consultant Pathologist



Page 3 Of 17

View Report

t

View Details

Ē



Ð

PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR : S	SELF
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017		AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04
Test Report Status Final	Results Biological	Reference Interval Units

0 - 14

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE **ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE** BLOOD E.S.R 06

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.

Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall

(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. <h>TEST INTERPRETATION</h>

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease

(Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.



Dr. Akansha Jain **Consultant Pathologist**



Q 🗖

Page 4 Of 17

mm at 1 hr



PATIENT NAME : SUDHIR KASLIWAL REF. DOCTOR	R: SELF
CODE/NAME & ADDRESS : C000049066 ACCESSION NO: 0251WJ001886 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AKRITI LABS PVT LTD. A-430, AGRASEN MARG PATIENT ID : SUDHM211066251 JAIPUR 302017 9314660100 ABHA NO :	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04

Test Report	Status	<u>Final</u>
-------------	--------	--------------

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE O METHOD : TUBE AGGLUTINATION TYPE O RH TYPE POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain Consultant Pathologist



Page 5 Of 17

View Report





CODE/NAME & ADDRESS : C000049066 ACCESSION NO : 02	251WJ001886 AG	CE/CEV .	E 3 1/	
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-	UDHM211066251		57 Years 21/10/2023	Male 12:57:00
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG LAIPUR 302017	: 012310210045 RE	ECEIVED :	21/10/2023	13:02:30
9314660100 ABHA NO :	RE	EPORTED :	24/10/2023	14:14:04

Test Report Status	<u>Final</u>	Results	Biological Reference Interva	al Units
ſ				
		BIOCHEMISTRY		
	SODY HEALTH CHECK UP	ABOVE 40 MALE		
GLUCOSE FASTING,F	LUORIDE PLASMA			
FBS (FASTING BLOO METHOD : GLUCOSE OXIDA		118 High	74 - 99	mg/dL
GLUCOSE, POST-PRA	ANDIAL, PLASMA			
PPBS(POST PRANDIA METHOD : GLUCOSE OXIDAS	,	195 High	70 - 140	mg/dL
LIPID PROFILE WIT	H CALCULATED LDL			
CHOLESTEROL, TOTA	4L	185	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL O>	XIDASE			
TRIGLYCERIDES		105	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : LIPASE/GPO-PAP	NO CORRECTION	35 Low		ma/dl
HDL CHOLESTEROL		35 LOW	< 40 Low >/=60 High	mg/dL
CHOLESTEROL LDL		129 High	< 100 Optimal 100 - 129 Near optimal/ above optima 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL al
NON HDL CHOLESTE	ROL	150 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL)
			very highly of 220	

METHOD : CALCULATED PARAMETER

Dr. Akansha Jain **Consultant Pathologist**



t







PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 02 PATIENT ID : SL CLIENT PATIENT ID: ABHA NO :	DHM211066251	1	:57 Years Male :21/10/2023 12:57:00 :21/10/2023 13:02:30 :24/10/2023 14:14:04
Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval Units
	21.0	20 0</td <td></td> <td>ma/dl</td>		ma/dl

VERY LOW DENSITY LIPOPROTEIN CHOL/HDL RATIO	21.0 5.3 High	= 30.0<br 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	mg/dL
LDL/HDL RATIO	3.7 High	0.5 - 3.0 Desirable/Low Ris 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk	

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target. Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category						
Extreme risk group	A.CAD with	A.CAD with > 1 feature of high risk group				
	B. CAD wit	h > 1 feature of Very hi	igh risk g	roup or recurre	nt ACS (within 1 ye	ear) despite LDL-C < or =
	50 mg/dl or	polyvascular disease		-		
Very High Risk	1. Establishe	ed ASCVD 2. Diabetes	s with 2 r	najor risk facto	rs or evidence of en	d organ damage 3.
	Familial Ho	mozygous Hypercholes	terolemia	1		
High Risk	1. Three ma	jor ASCVD risk factor	s. 2. Dia	betes with 1 m	ajor risk factor or no	o evidence of end organ
		CKD stage 3B or 4. 4.				
	Artery Calci	um - CAC >300 AU. 7	 Lipopr 	otein a >/= 50n	ng/dl 8. Non stenot	ic carotid plaque
Moderate Risk	2 major AS	2 major ASCVD risk factors				
Low Risk	0-1 major ASCVD risk factors					
		ardiovascular disease)		ctors		
1. Age > or = 45 years	ears in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use					
2. Family history of pr	story of premature ASCVD 4. High blood pressure					
5. Low HDL						
Newer treatment goals	and statin in	itiation thresholds bas	sed on th	e risk categori	es proposed by LA	I in 2020.
Risk Group		Treatment Goals		Consider Drug T	herapy	
		LDL-C (mg/dl)	Non-H	DL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group (Category A	<50 (Optional goal	< 80 (0	Optional goal	>OR = 50	>OR = 80
		< OR = 30)	<or =<="" td=""><td>60)</td><td></td><td></td></or>	60)		

Dr. Akansha Jain **Consultant Pathologist**



÷,







PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000049066	ACCESSION NO : 0251WJ001886	AGE/SEX : 57 Years Male
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG	PATIENT ID : SUDHM211066251	DRAWN :21/10/2023 12:57:00
JAIPUR 302017	CLIENT PATIENT ID: 012310210045	RECEIVED : 21/10/2023 13:02:30
9314660100	ABHA NO :	REPORTED :24/10/2023 14:14:04

Test	Report	Status	Final

Results

Biological Reference Interval Units

Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td><td></td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td><td></td></or>	> 30	>60	
Very High Risk	<50	<80	>OR= 50	>OR= 80	
High Risk	<70	<100	>OR= 70	>OR=100	
Moderate Risk	<100	<130	>OR=100	>OR=130	
Low Risk	<100	<130	>OR=130*	>OR=160	
*After an adequate non-pharmacolog	ical intervention for	at least 3 months.			
References: Management of Dyslipio			cal Practice Recommend	ations from the Lipid A	ssociation o
India. Current Vascular Pharmacolog		5.			
LIVER FUNCTION PROFILE, SE	ERUM				
BILIRUBIN, TOTAL		0.51	0 - 1		mg/dL
METHOD : DIAZO WITH SULPHANILIC ACI	Ď				
BILIRUBIN, DIRECT		0.14	0.00 - 0.	25	mg/dL
, METHOD : DIAZO WITH SULPHANILIC ACI	D				_
BILIRUBIN, INDIRECT		0.37	0.1 - 1.0		mg/dL
METHOD : CALCULATED PARAMETER					0.
TOTAL PROTEIN		7.2	6.4 - 8.2		g/dL
METHOD : BIURET REACTION, END POINT					5,
ALBUMIN		4.2	3.8 - 4.4		g/dL
METHOD : BROMOCRESOL GREEN		112	5.0 111		5/
GLOBULIN		3.0	2.0 - 4.1		g/dL
METHOD : CALCULATED PARAMETER		5.0	2.0 7.1		9/42
ALBUMIN/GLOBULIN RATIO		1.4	1.0 - 2.1		RATIO
METHOD : CALCULATED PARAMETER		1.4	1.0 - 2.1		NAII0
		20	0 - 37		U/L
ASPARTATE AMINOTRANSFER	ASE	20	0 - 37		0/L
(AST/SGOT) METHOD : TRIS BUFFER NO P5P IFCC / SF	-DC 370 C				
ALANINE AMINOTRANSFERAS		17	0 - 40		U/L
METHOD : TRIS BUFFER NO P5P IFCC / SF	,	17	0 - 40		0/L
ALKALINE PHOSPHATASE	BC 37° C	60	39 - 117		U/L
		00	59 - 117		0/L
METHOD : AMP OPTIMISED TO IFCC 37° C		10	11 50		11/1
GAMMA GLUTAMYL TRANSFER	· · ·	16	11 - 50		U/L
METHOD : GAMMA GLUTAMYL-3 CARBOXY	-4 NITROANILIDE (IFCC)		222 46	^	11/1
LACTATE DEHYDROGENASE		343	230 - 46	U	U/L
DLOOD UDEA NITTOOCEN (DUA					

BLOOD UREA NITROGEN (BUN), SERU	М		
BLOOD UREA NITROGEN	8	5.0 - 18.0	mg/dL
METHOD : UREASE KINETIC			

Dr. Akansha Jain Consultant Pathologist



0673

Page 8 Of 17

View Report

Υ.



Ö,



 \mathbf{B}



PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR : S	SELF
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG IAIPUR 302017	PATIENT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

CREATININE, SERUM CREATININE METHOD : ALKALINE PICRATE NO DEPROTEINIZATION	1.19	0.8 - 1.3	mg/dL
BUN/CREAT RATIO BUN/CREAT RATIO METHOD : CALCULATED PARAMETER	6.72		
URIC ACID, SERUM URIC ACID METHOD : URICASE PEROXIDASE WITH ASCORBATE OXIDASE	6.4	3.4 - 7.0	mg/dL
TOTAL PROTEIN, SERUM TOTAL PROTEIN METHOD : BIURET REACTION, END POINT	7.2	6.4 - 8.3	g/dL
ALBUMIN, SERUM ALBUMIN METHOD : BROMOCRESOL GREEN	4.2	3.8 - 4.4	g/dL
GLOBULIN GLOBULIN	3.0	2.0 - 4.1	g/dL

ELECTROLYTES (NA/K/CL), SERUM

Dr. Akansha Jain Consultant Pathologist









PATIENT NAME : SUDHIR KASLIWAL CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	REF. ACCESSION NO : 0251WJO PATIENT ID : SUDHM21: CLIENT PATIENT ID: 0123102: ABHA NO :	L066251 DRAV L0045 RECE	
Test Report Status <u>Final</u>	Results	Biological Refe	rence Interval Units
SODIUM, SERUM METHOD : ION-SELECTIVE ELECTRODE POTASSIUM, SERUM	142.0 4.15	137 - 145 3.6 - 5.0	mmol/L mmol/L
METHOD : ION-SELECTIVE ELECTRODE CHLORIDE, SERUM METHOD : ION-SELECTIVE ELECTRODE	101.4	98 - 107	mmol/L

Sodium	Potassium	Chloride
Decreased In:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency,	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's	Decreased In: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis,
nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide,carbamazepine,anti depressants (SSRI), antipsychotics.	syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

control description of the synthesis of the synthesis

insulin_ethanol.propranolol;sulfonylureas.tolbutamide,and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.



Dr. Akansha Jain **Consultant Pathologist**



Page 10 Of 17





PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTO	DR: SELF
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251WJ001886 PATIENT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045 ABHA NO :	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04
Test Report Status Final	Results Biolog	gical Reference Interval Units

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed,Alimentary Hypoglycemia,Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

 may give yellow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert

syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly

measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

 Abbr and the second sec

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT

and globulin.Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to: . Myasthenia Gravis, Muscuophy
URIC ACID, SERUM-Causes of Increased levels: . Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2

DM,Metabolic syndrome

Social Social

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood

serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.



Dr. Akansha Jain **Consultant Pathologist**



Page 11 Of 17

View Report





Biological Reference Interval Units

PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR :	: SELF
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251WJ001886 PATIENT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045 ABHA NO :	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04

Results

CLINI	CAL PATH - URINALYS	S	
MEDI WHEEL FULL BODY HEALTH CHECK UP A	BOVE 40 MALE		
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
METHOD : GROSS EXAMINATION			
APPEARANCE	CLEAR		
METHOD : GROSS EXAMINATION			
CHEMICAL EXAMINATION, URINE			
PH	5.5	4.7 - 7.5	
METHOD : DOUBLE INDICATOR PRINCIPLE	1.015	1 002 1 025	
SPECIFIC GRAVITY METHOD : IONIC CONCENTRATION METHOD	1.015	1.003 - 1.035	
PROTEIN	NOT DETECTED	NEGATIVE	
METHOD : PROTEIN ERROR OF INDICATORS WITH REFLECTANCE			
GLUCOSE	NOT DETECTED	NEGATIVE	
METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS			
KETONES METHOD : SODIUM NITROPRUSSIDE REACTION	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NEGATIVE	
METHOD : PEROCIDASE ANTI PEROXIDASE		-	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
METHOD : DIPSTICK	NORMAL	NORMAL	
UROBILINOGEN METHOD : EHRLICH REACTION REFLECTANCE	NORMAL	NORMAL	
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD : NITRATE TO NITRITE CONVERSION METHOD			
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : DIPSTICK, MICROSCOPY			

Test Report Status

<u>Final</u>

Dr. Akansha Jain **Consultant Pathologist**



Page 12 Of 17





PATIENT NAME : SUDHIR KASLIWAL		REF. DOCTOR :	SELF		
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 025 PATIENT ID : SUDI CLIENT PATIENT ID: 01 ABHA NO :	HM211066251	DRAWN RECEIVED	:57 Years :21/10/2023 1: :21/10/2023 1: :24/10/2023 14	3:02:30
Test Report Status <u>Final</u>	Results	Biological	Reference	e Interval Un	its
EPITHELIAL CELLS METHOD : MICROSCOPIC EXAMINATION	0-1	0-5		/HPF	
CASTS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED				

METHOD : MICROSCOPIC EXAMINATION CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION BACTERIA	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION YEAST	NOT DETECTED	NOT DETECTED

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr. Akansha Jain **Consultant Pathologist**

Page 13 Of 17

÷,







PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR :	SELF
ACTUUS DIACNOSTICS LIMITED-WEL WALK-IN-	ACCESSION NO : 0251WJ001886	AGE/SEX : 57 Years Male DRAWN : 21/10/2023 12:57:00
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG	PATIENT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045	RECEIVED : 21/10/2023 13:02:30
9314660100	ABHA NO :	REPORTED :24/10/2023 14:14:04

Test Report Status Final Results Biological Reference Interval
--

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain Consultant Pathologist



Page 14 Of 17

View Report

View Details

ΟŤ





PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR :	: SELF
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251WJ001886 PATIENT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045 ABHA NO :	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04

Test Report Status Final

Results

Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, STOOL

COLOUR

METHOD : GROSS EXAMINATION

SAMPLE NOT RECEIVED

Dr. Abhishek Sharma Consultant Microbiologist



Page 15 Of 17

View Report





PATIENT NAME : SUDHIR KASLIWAL		REF. DOCTOR	SELF		
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD. A-430, AGRASEN MARG JAIPUR 302017 9314660100	PATIENT ID	: 0251WJ001886 : SUDHM211066251 ID: 012310210045 :	DRAWN RECEIVED	:57 Years :21/10/2023 :21/10/2023 :24/10/2023	13:02:30
Test Report Status <u>Final</u>	Results	Biologica	al Reference	e Interval l	Jnits

	SPECIALISED CHEMISTRY -	HORMONE	
MEDI WHEEL FULL BODY HEALTH CH	ECK UP ABOVE 40 MALE		
THYROID PANEL, SERUM			
T3 METHOD : CHEMILUMINESCENCE	91.09	60.0 - 181.0	ng/dL
T4 METHOD : CHEMILUMINESCENCE	9.70	4.5 - 10.9	µg/dL
TSH (ULTRASENSITIVE) METHOD : CHEMILUMINESCENCE	1.053	0.550 - 4.780	µIU/mL

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
		-	-	-	(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Akansha Jain **Consultant Pathologist**













PATIENT NAME : SUDHIR KASLIWAL	REF. DOCTOR :	SELF
ACTUUS DIAGNOSTICS LIMITED-WEL WALK-IN-	ACCESSION NO : 0251WJ001886 РАТІЕNT ID : SUDHM211066251 CLIENT PATIENT ID: 012310210045 АВНА NO :	AGE/SEX :57 Years Male DRAWN :21/10/2023 12:57:00 RECEIVED :21/10/2023 13:02:30 REPORTED :24/10/2023 14:14:04

Test Report Status <u>Final</u> Results Biological Reference Interval Un	Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units
--	--------------------	--------------	---------	-------------------------------------

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	 Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	 T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession


Dr. Akansha Jain Consultant Pathologist



Page 17 Of 17

View Report







Aakriti Labs 3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN NO.: U85195RJ2004PTC019563

Name : Mr. SUDHIR KASLIWAL Age/Gender: 57 Y/Male Patient ID : 012310210045 BarcodeNo :10102899 Referred By : Self

Registration No: 68642

Registered	÷	21/Oct/2023 12:57PM
Analysed	1	24/Oct/2023 12:53PM
Reported	2	24/Oct/2023 12:53PM
Panel	:	MEDI WHEEL (ARCOFEMI HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Male)

LIVER : Is normal in size, shape and echogenecity. The IHBR and hepatic radicals are not dilated. No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and common bile duct appear normal.

GALL : Is not visualized. H/o Cholecystectomy. BLADDER

PANCREAS : Is normal in size, shape and echotexture. Pancreatic duct is not dilated. SPLEEN : Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS : Right Kidney is not visualized. H/o Operation , Left Kidney:-Size: 93 x 56 mm. Left Kidney is normal in size,shape and echotexture. corticomedullary differentiation is fait and ratio appears normal. Pelvi calyceal system is normal.No evidence of hydronephrosis/ nephrolithiasis.

URINARY : Bladder walls are smooth, regular and normal thickness. BLADDER :No evidence of mass or stone in bladder lumen.

PROSTATE: Is normal in size, shape and echotexture, measures: 32 x 29 x 24 mm, wt: 12 gms. Its capsule is intact and no evidence of focal lesion.

SPECIFIC : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity. No evidence of lymphadenopathy or mass lesion in retroperitoneum. Visualized bowel loop appear normal.Great vessels appear normal.

IMPRESSION :- NORMAL STUDY.

*** End Of Report ***

Page 1 of

Dr. Neera Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853



ALPL policy mandates the film records to be maintained for a prind of 3 significationly colled; the film before the percents of the percents of the percents of the percent of the percent



🛸 Aakriti Labs 3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

NAME		MR SUDHIR KASLIWAL		AGE	57Y		SEX	MALE	
REF BY	MEDI WHEEL HEALTH		DATE 24/10/2023		023	REG NO			
			ECH	OCARDIOG	RAM RE	PORT	and the second second	and a second	
	/- POO	R/ADEQU	JATE/G	OODVALVE					
MITRAL		1	NORMA	il.	TRICU	SPID		NORMA	L
AORTIC		1	NORMA	L.	PULMONARY		NORMAL		
2D/M-M	DD				1100				
IVSD mm 8.8			IVSS mm	9.5	9.5 AC		A mm	32.8	
LVID mm	-	41.6	_	LVIS mm	22.7		LA mr	n	25.7
LVPWD m		9.5	_	LVPWS mm	6.4		EF%		60%
CHAMBER	RS								
LA			N	DRMAL	RA	RA		NOR	MAL
LV		N	DRMAL	RV	RV		NOR	and in case of the local division of the loc	
PERICARDIUM			ORMAL		-	_			
DOPPLER	Contraction of the local division of the loc	and the state of t				-		-	_
PEAK VELOCITY m/s E/A		0.9	93/0.62	PEA	PEAK GRADIANT MmHg		6	_	
MEAN VELOCITY m/s					MEAN GRADIANT MmHg				
MVA cm2 (PLANITMETERY)		Y)			MVA cm2 (PHT)		0		
MR								_	
AORTIC									
PEAK VELOCITY m/s		0.8	35	PEAN	GRADIANT	MmHg			
MEAN VELOCITY m/s					MEAN GRADIANT MmHg				
AR									
RICUSPID	1								_
PEAK VELOCITY m/s		0.7	3	PEAK	PEAK GRADIANT MmHg		27		
MEAN VEL	OCITY	m/s		VV		MEAN GRADIANT MmHg			
rR					PASP mmHg				
ULMONA				17	-		-		
EAK VELO		and the second s	1.4	2	PEAK	PEAK GRADIANT MmHg			_
AEAN VEL	OCITY	m/s				MEAN GRADIANT MmHg		2	
PR					PmmHg		e	_	

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION ٠
- . NO RWMA LVEF 60%
- NORMAL RV FUNCTION •
- . NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO ٠
- ٠ INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM. ٠
- ٠ **IVC NORMAL**

CONCLUSION : FAIR LV FUNCTION.

Cardiologist

.

Iness	Aakriti Labs 3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN NO.: U85195RJ2004PTC019563		
lame	: Mr. SUDHIR KASLIWAL	Age/Sex	: 57 Yrs/ MALE
Ref.By	: AAKRATI LABS	Date	:24 October 2023

RADIOGRAPH OF CHEST : PA VIEW

P.S. Vertical linear film artefacts present overlapping both lungs fields. Suboptimal contrast factor settings creating artefacts in the region of interest leading to suboptimal evaluation. No history provided in regards to x ray done. Reporting is done with these limitations.

Rotation artefacts prsent.

Soft tissue and bony cage are normal.

Both lungs are clear.

Both domes of diaphragm are normal in position and contour.

Hilar shadows are normal.

Mediastinum is central.

Both costo-phrenic angles are clear.

Cardio-thoracic ratio is normal with normal heart borders.

IMPRESSION:

NO OBVIOUS ABNORMALITY.

DR. SHUBHAM SINGHAL CONSULTANT RADIOLOGIST